Add time:08/14/2019         Source:sciencedirect.com

Although mutated Ras protein is well recognized as an important drug target, direct targeting Ras has proven to be a daunting task. Recent studies demonstrated that Ras protein needs PDEδ to relocate to plasma membrane to execute its signaling transduction function, which provides a new avenue for modulating the Ras protein. To find small molecules antagonizing the interactions between PDEδ and Ras, here we presented a successful application of fragment-based drug discovery of PDEδ inhibitors. Under the guidance of crystal structures, we are able to quickly optimize the initial fragment into highly potent inhibitors, with more than 2000-fold improvement in binding activity, which further adds to the arsenal towards the inhibition of Ras signaling in cancer therapy.

We also recommend Trading Suppliers and Manufacturers of 4-PHENYL-5-PYRIDIN-4-YL-4H-[1,2,4]TRIAZOLE-3-THIOL (cas 16629-40-6). Pls Click Website Link as below: cas 16629-40-6 suppliers